Literature DB >> 26106177

Bony non-union in a patient receiving androgen deprivation therapy for prostate cancer.

Adeel Ikram1, Jagwant Singh2, Ahmad Ali3.   

Abstract

We present a case of a 76-year-old man who underwent a corrective femoral osteotomy for a varus deformity and stress fractures. The patient was on androgen deprivation therapy (ADT) for prostate cancer and the osteotomy failed to heal. At 13 months, the ADT was stopped and bony union was achieved in 3 months. Orthopaedic surgeons treating fractures in this patient population need to aware of the problems associated with ADT and closely liaise with oncologists and urologists to stop ADT or start alternative treatment until bony union has been achieved. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26106177      PMCID: PMC4480135          DOI: 10.1136/bcr-2015-209950

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  18 in total

1.  Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression.

Authors:  Celestia Higano; Andrew Shields; Nathanael Wood; Judy Brown; Cathy Tangen
Journal:  Urology       Date:  2004-12       Impact factor: 2.649

2.  Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.

Authors:  Susan L Greenspan; Penelope Coates; Susan M Sereika; Joel B Nelson; Donald L Trump; Neil M Resnick
Journal:  J Clin Endocrinol Metab       Date:  2005-09-27       Impact factor: 5.958

3.  Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma.

Authors:  J F Maillefert; J Sibilia; F Michel; C Saussine; R M Javier; C Tavernier
Journal:  J Urol       Date:  1999-04       Impact factor: 7.450

4.  Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.

Authors:  Alfredo Berruti; Luigi Dogliotti; Carlo Terrone; Stefania Cerutti; Giancarlo Isaia; Roberto Tarabuzzi; Giuseppe Reimondo; Mauro Mari; Paola Ardissone; Stefano De Luca; Giuseppe Fasolis; Dario Fontana; Salvatore Rocca Rossetti; Alberto Angeli
Journal:  J Urol       Date:  2002-06       Impact factor: 7.450

5.  Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.

Authors:  M R Smith; F J McGovern; A L Zietman; M A Fallon; D L Hayden; D A Schoenfeld; P W Kantoff; J S Finkelstein
Journal:  N Engl J Med       Date:  2001-09-27       Impact factor: 91.245

6.  Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).

Authors:  Richard Eastell; Rosemary A Hannon; Jack Cuzick; Mitch Dowsett; Glen Clack; Judith E Adams
Journal:  J Bone Miner Res       Date:  2006-08       Impact factor: 6.741

7.  Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs.

Authors:  Daniella Mittan; Shuko Lee; Elizabeth Miller; Reina C Perez; Joseph W Basler; Jan M Bruder
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

8.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

9.  Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

Authors:  M Dror Michaelson; Donald S Kaufman; Hang Lee; Francis J McGovern; Philip W Kantoff; Mary Anne Fallon; Joel S Finkelstein; Matthew R Smith
Journal:  J Clin Oncol       Date:  2007-03-20       Impact factor: 44.544

10.  Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF).

Authors:  I Fogelman; G M Blake; R Blamey; M Palmer; W Sauerbrei; M Schumacher; D Serin; A Stewart; W Wilpshaar
Journal:  Osteoporos Int       Date:  2003-10-03       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.